Cargando…

Utilization Patterns of Coagulation Factor Consumption for Patients with Hemophilia

Hemophilia is a serious rare disease that requires continuous management and treatment for which the medicine is costly at the annual average of 100 million KRW for an individual. The aim of this study was to investigate trends in the utilization of coagulation factor (CF) used for hemophilia treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Soo Ok, Yu, Su-Yeon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4712577/ https://www.ncbi.nlm.nih.gov/pubmed/26770035 http://dx.doi.org/10.3346/jkms.2016.31.1.33

Ejemplares similares

Coagulation Factor IX for Hemophilia B Therapy 
por: Orlova, N. A., et al.
Publicado: (2012)

Effects of coagulation factor concentrate prophylaxis in moderate and severe hemophilia A patients at a single hemophilia center in Korea
por: Moon, Byung Suk, et al.
Publicado: (2013)

Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2018)

Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy
por: Mast, Alan E., et al.
Publicado: (2022)

Quality of clinical studies present in the package inserts of coagulation factors used in the treatment of hemophilia
por: Araújo, Yasmin Gonçalves, et al.
Publicado: (2022)

Global coagulation assays in hemophilia A: A comparison to conventional assays
por: Aghighi, Saman, et al.
Publicado: (2019)

Understanding the impact of unequal utilization of medical services on the consumption of resources in hemophilia
por: Li, Lele, et al.
Publicado: (2022)

Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients
por: Ar, Muhlis Cem, et al.
Publicado: (2019)

STUDIES ON BLOOD COAGULATION : IV. THE NATURE OF THE CLOTTING DEFICIENCY IN HEMOPHILIA
por: Eagle, Harry
Publicado: (1935)

Descriptive Epidemiology of Hemophilia and Other Coagulation Disorders in Mansoura, Egypt: Retrospective Analysis.
por: Al Tonbary, Youssef, et al.
Publicado: (2010)

Costs and utilization of treatment in patients with hemophilia
por: Rocha, Patrícia, et al.
Publicado: (2015)

Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
por: Heestermans, Marco, et al.
Publicado: (2017)

Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan – A Population-Based Study
por: Hsieh, Miyuki Hsing-Chun, et al.
Publicado: (2022)

Deletion of Coagulation Factor IX Compromises Bone Mass and Strength: Murine Model of Hemophilia B (Christmas Disease)
por: Larson, Emily A., et al.
Publicado: (2021)

Therapeutic Effects of Kefir Peptides on Hemophilia-Induced Osteoporosis in Mice With Deficient Coagulation Factor VIII
por: Yen, Chih-Ching, et al.
Publicado: (2022)

Correction of the coagulation defect in hemophilia using a factor Xa variant with novel engineered protease function
por: Ivanciu, Lacramioara, et al.
Publicado: (2011)

MG1113, a specific anti–tissue factor pathway inhibitor antibody, rebalances the coagulation system and promotes hemostasis in hemophilia
por: Kwak, Heechun, et al.
Publicado: (2020)

Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
por: Doshi, Bhavya S., et al.
Publicado: (2012)

Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia
por: Thorat, Teja, et al.
Publicado: (2018)

Coagulation assessment with thromboelastography during abdominal endovascular aneurysm repair in a patient with hemophilia A
por: Sato, Kazuki, et al.
Publicado: (2020)

Peri-cardiac surgery coagulation management in a severe hemophilia A patient: A case report
por: Xu, Hongfei, et al.
Publicado: (2019)

Compensated pathogenic variants in coagulation factors VIII and IX present complex mapping between molecular impact and hemophilia severity
por: Marín, Òscar, et al.
Publicado: (2019)

CRISPR/Cas9‐mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse
por: Guan, Yuting, et al.
Publicado: (2016)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

The Utility of Antiseptics and Coagulants in Composting Habitation Wastes
por: Nicholson, M. A., et al.
Publicado: (1936)

P1670: LONG TERM SAFETY AND EFFICACY OF RECOMBINANT HUMAN COAGULATION FACTOR VIII (SCT800) IN PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
por: Xue, F., et al.
Publicado: (2022)

Bioengineering coagulation factors for improved hemophilia treatments(): Comment on: the mutation F309S increases FVIII secretion in human cell line
por: Hounkpe, Bidossessi Wilfried, et al.
Publicado: (2016)

Practice of Iranian Adolescents with Hemophilia in Prevention of Complications of Hemophilia
por: Valizadeh, Leila, et al.
Publicado: (2015)

Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature
por: He, Jin Peng, et al.
Publicado: (2017)

Real-world utilities and health-related quality-of-life data in hemophilia patients in France and the United Kingdom
por: Carroll, Liz, et al.
Publicado: (2019)

Novel Coagulation Factor VIII Gene Therapy in a Mouse Model of Hemophilia A by Lipid-Coated Fe(3)O(4) Nanoparticles
por: Kao, Yung-Tsung, et al.
Publicado: (2021)

Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A
por: Colombo, Giorgio L, et al.
Publicado: (2011)

A patient with acquired hemophilia A induced by clopidogrel
por: Hwang, Hye Won, et al.
Publicado: (2012)

The Consumption of Some Components Involved in Physiological Blood Coagulation
por: Douglas, A. S., et al.
Publicado: (1953)

Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV Infection
por: Tencer, Thomas, et al.
Publicado: (2007)

Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A
por: Hyun, Shin Young, et al.
Publicado: (2015)

Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients
por: Owaidah, Tarek M., et al.
Publicado: (2020)

Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia A following liver-directed adeno-associated viral vector delivery
por: Brown, Harrison C, et al.
Publicado: (2014)

Clinical Utility of Subcutaneous Factor VIII Replacement Therapies in Hemophilia A: A Review of the Evidence
por: Dargaud, Yesim, et al.
Publicado: (2021)

The Utilization of Rehabilitation in Patients with Hemophilia A in Taiwan: A Nationwide Population-Based Study
por: Chen, Chien-Min, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j4n5jtlqdbciar52nt3p0kfd43